Containing Heavy Metal Or Salt Thereof Patents (Class 930/25)
  • Patent number: 7888311
    Abstract: The invention concerns uranium-chelating peptides as well as their uses for decontaminating soils and water, and for detecting and treating people contaminated by uranium. Said peptides have a helix-loop-helix type structure comprising the sequence of a calmodulin loop including at least one mutation of neutral residues selected from the group consisting of S, T, C, H, Y, N and Q, of one, two or three residues of at least one of the four calmodulin calcium binding sites: site I: residues selected among D20, D22 and D24 residues; site II: residues selected among D56, D58 and N60 residues; site III: residues selected among D93, D95 and N97 residues; site IV: residues selected among D129, D131 and D133 residues; said positions being indicated with reference to the human calmodulin sequence.
    Type: Grant
    Filed: July 1, 2004
    Date of Patent: February 15, 2011
    Assignee: Commissariat a l'Energie Atomique
    Inventors: Claudio Vita, Mireille Sauvage-Vita, legal representative, Fabio Vita, legal representative, Elena Vita, legal representative, Loïc Le Clainche, Véronique Monjardet
  • Patent number: 7384916
    Abstract: Disclosed are methods for treating aging and photodamaged skin employing topical application of compositions which comprise at least one peptide manganese complex. Also disclosed are methods wherein the composition further comprises retinol, at least one retinol derivative, or a mixture thereof and methods wherein the composition further comprises active agents selected from active drug substances, emollients, sunscreen agents, skin lightening agents, skin protectants, skin conditioning agents, humectants, and mixtures thereof.
    Type: Grant
    Filed: March 15, 2006
    Date of Patent: June 10, 2008
    Assignee: ProCyte Corporation
    Inventor: Leonard M. Patt
  • Patent number: 5679548
    Abstract: The present invention describes methods for producing metal binding sites on polypeptides, and particularly for producing metal binding sites within the CDR regions of immunoglobulin heavy or light chains that are displayed on the surface of filamentous phage particles. The invention also describes oligonucleotides useful for preparing the metal binding sites, and human monoclonal antibodies produced by the present methods.
    Type: Grant
    Filed: June 14, 1993
    Date of Patent: October 21, 1997
    Assignee: The Scripps Research Institute
    Inventors: Carlos F. Barbas, Jonathan Rosenblum, Richard A. Lerner
  • Patent number: 5281704
    Abstract: There are disclosed polychelant compounds, that is multi-site metal chelating agents, and chelates formed therewith. The polychelants and especially their paramagnetic metal, heavy metal or radioactive metal polychelates are particularly suitable for use in diagnostic imaging, heavy metal detoxification or radiotherapy. The polychelants have a linear or branched oligomeric structure comprising alternating chelant and linker moieties bound together by amide or ester moieties the carbonyl groups whereof being adjacent the chelant moieties, each polychelant comprising at least two said chelant moieties capable of complexing a metal ion.
    Type: Grant
    Filed: January 19, 1990
    Date of Patent: January 25, 1994
    Assignee: Salutar, Inc.
    Inventors: David B. Love, William C. Dow, Richard J. Himmelsbach, Alan D. Watson, Scott M. Rocklage
  • Patent number: 5149785
    Abstract: The present invention is directed to genes, termed Rpt-1 (regulatory protein T lymphocyte-1), which are expressed at higher levels by resting CD4.sup.+ helper/inducer T cells relative to activated CD4.sup.+ cells. The invention also relates to the proteins encoded by such genes, termed rpt-1 proteins, which regulate gene expression directed by the promoter region of the interleukin-2 receptor (IL-2r) alpha chain gene or by the promoter region of the long terminal repeat of human lymphotropic retroviruses such as the human immunodeficiency virus type 1 (HIV-1), human T cell leukemia virus (HTLV-I, and HTLV-II. In particular, rpt-1 proteins down-regulate gene expression controlled by the promoter of the IL-2r alpha chain gene or by the promoter of the long terminal repeat of HIV-1. The proteins and nucleic acids of the invention have value in diagnosis and therapy of immune disorders such as AIDS.
    Type: Grant
    Filed: February 21, 1990
    Date of Patent: September 22, 1992
    Assignee: Dana-Farber Cancer Institute
    Inventors: Harvey I. Cantor, Roberto Patarca, Gordon J. Freeman